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Abstract
Enterovirus 71 (EV71) has emerged as a significant pathogen causing large outbreaks in China for the past 3 years.
Developing an EV71 vaccine is urgently needed to stop the spread of the disease; however, the adaptive immune
response of humans to EV71 infection remains unclear. We examined the neutralizing antibody titers in HFMD
patients and compared them to those of asymptomatic healthy children and young adults. We found that 80% of
HFMD patients became positive for neutralizing antibodies against EV71 (GMT = 24.3) one day after the onset of
illness. The antibody titers in the patients peaked two days (GMT = 79.5) after the illness appeared and were
comparable to the level of adults (GMT = 45.2). Noticeably, the antibody response was not correlated with disease
severity, suggesting that cellular immune response, besides neutralizing antibodies, could play critical role in
controlling the outcome of EV71 infection in humans.
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Background
Historically, the outbreaks of HFMD (hand, foot and
mouth disease) in European countries and the United
States have been spontaneous and small in scale.
Noticeably, there were also two large outbreaks with
high mortality rates in Bulgaria (1975) [1] and Hungary
(1978) [2]. In recent years numerous large outbreaks of
HFMD have occurred in eastern and southeastern Asian
countries and regions, including Malaysia [3], Singapore
[4], Taiwan [5], Japan [6], South Korea [7], Vietnam [8]
and mainland China [9]. HFMD has become an emer-
ging disease in China since March 2008 [10]. Accumu-
lating cases so far have reached 3.4 million, including
nearly 1400 fatalities. It is worth mentioning that not
only deaths have increased 156% over the last year, but
the overall number of severe cases has also increased
significantly. The noticeable difference of these out-
breaks in China from other regions is that the
circulating EV71 viruses are only from the C4 genotype
[11], but the reasons for causing large outbreaks in
China still remains largely unclear. Environmental,
human genetic and immunological factors all have, most
likely, contributed to it.
In recent years, several EV71 vaccine candidates,
including live-attenuated virus, inactivated whole virus,
recombinant viral protein, virus-like particle and DNA
vaccine, have been evaluated in animal studies [12-17].
The vaccine studies in animal models have demon-
strated that neutralizing antibodies may play a critical
role in protecting mice from the viral challenge
[12,13,16]. EV71 vaccine clinical trials have been
approved recently and will be soon carried out in China.
Other than the target populations, it is difficult to pre-
dict what antibody titer will be considered as a protec-
tive level in the clinical trials. Probably the best way to
discover this information is to study naturally-occurring
EV71 infections in patients.
Because the current outbreak in China began in
March 2008 in the city of Fuyang, located in northwes-
tern Anhui province [18], we retrospectively compared
the antibody response of patients to EV71 infection in
Fuyang to asymptomatic healthy children and young
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against EV71 was detectable one day after symptoms
manifested and reached peak levels 2 days afterwards.
To our surprise, the antibody response was not corre-
lated with severity of the disease. In addition, more than
17% patients had less than a 1:16 neutralizing antibody
titer. Thus, our data suggests that the neutralizing anti-
body may not be the only mechanisms protecting adults
as well as children from EV71 infection.
Results
In 2008, there were 7,470 reported cases of HFMD in
t h ec i t yo fF u y a n gd u r i n gt h ep e r i o df r o mM a r c h1t o
May 31, of which 4840 patients were hospitalized and
23 cases were fatal (case fatality rate = 0.31%). The
number of cases, according to date of onset, began to
increase in early April and peaked on April 28. The
number of reported HFMD cases in Fuyang decreased
after May 5. RT-PCR analysis of EV71 nucleic acid
revealed that 69 of 161 cases (60.3%) were positive in
various specimens, including pharyngeal swabs, lung
puncture fluid, lung tissues and blood. All of them were
negative in RT-PCR analysis of Coxsackievirus A16
(CA16) nucleic acid. Therefore, EV71 but not CA16 was
determined to be the causative pathogen.
In this study, we analyzed 58 HFMD patients and 60
healthy controls. Both groups ranged in age from 1 to 3
years old. Among the patients, 13 of them had typical
HFMD symptoms such as a skin rash and fever and
were assigned to the mild group. Twenty-eight patients
were critical with severe neurological pulmonary edema.
Seventeen had less CNS involvement such as poliomye-
litis-like syndrome, acute flaccid paralysis, encephalo-
myelitis, aseptic meningitis or encephalitis.
Similar to previous finding [10], we found that 41.2%
of HFMD-asymptomatic healthy children had neutraliz-
ing antibody titers of 1:8 or above against EV71 (geo-
metric mean titer, GMT = 7.4). The proportion of the
healthy controls that had neutralizing antibody titers ≥
1:16 and ≥ 1:64 dropped to 30.6% and 3.4%, respectively,
while none of them had ≥ 1:128 antibody titers. In con-
trast, 10 of 12 adults (83.3%) had neutralizing antibody
titers ≥ 1:16, which were significantly higher (GMT =
45.3) than those of the healthy children. Of note, 4 of
12 adults had neutralizing antibody titers ≥ 1:128
(Figure 1A).
Overall HFMD patients had remarkably higher levels of
neutralizing antibody titers (GMT = 72) than the healthy
controls (p < 0.01). The proportion of patients having neu-
tralizing antibody titers ≥ 1:8, ≥ 1:16, ≥ 1:32, ≥ 1:64, ≥
1:128, ≥ 1:256, ≥ 1:512 were 93.2%, 81.3%, 72.9%, 54.2%,
23.7%, 3.4% and 1.7%, respectively. The antibody titers in
the patients with CNS involvement or pulmonary edema
were not significantly different from those of patients with
mild HFMD [Figure 1B], suggesting that the neutralizing
antibody titers were not associated with the severity of the
disease.
Because the serum samples were collected at various
periods after the appearance of symptoms, we ques-
tioned whether the antibody titers were associated with
the collection times. Overall, our analysis revealed that
t h ea n t i b o d yt i t e r sw e r en o tc o r r e l a t e dw i t ht h ec o l l e c -
tion times. Noticeably, the serum samples collected one
day after the onset of illness had significantly lower
levels of neutralizing antibodies than the samples col-
lected at a later time [Figure 2A]. However, the neutra-
lizing antibody titers from the serum samples of patients
collected one day after falling ill (GMT = 24.3) were
already more than 3 times higher than that of healthy
control children (GMT = 7.4) [Figure 2B]. In addition, 4
of 5 patients had neutralizing antibody titers above 1:16.
These data suggest that neutralizing antibodies are typi-
cally produced when symptoms appear in patients.
Methods and materials
Human subjects and serum samples
The enrollment of HFMD patients was reported by
CDC to the WHO previously [18]. Accordingly, all the
patients had the following symptoms: 1) skin rash or
blisters on hand, foot, or buttock, and fever, in the
absence of measles, rubella, chicken pox and other feb-
rile eruption diseases; 2) skin rash or blisters on hand,
foot, or buttock, and ulcers on the mouth or mucous
membrane, in the absence of drug-related rash or
allergy. Severe cases were defined as having two of fol-
lowing clinical manifestations: 1) continuous high fever,
2) weakness, vomiting, irritability, etc., 3) abnormal
white blood cell count, 4) high blood glucose level or/
and 5) poor blood circulation of limbs. Pulmonary
edema was defined as respiratory distress, associated
with tachycardia, tachypnea, rales, and copious frothy
sputum, with a chest roentogenograph that showed
bilateral pulmonary infiltrates without cardiomegaly
[19].
Serum samples from control children, adults and
HFMD patients were collected by the Center for Disease
Control of Fuyang city for the purpose of national
HFMD surveillance in 2008 [18]. Written informed con-
sents were obtained for the use of serum samples from
all participants (or their parents). This study has been
approved by the ethics committee of Center for Disease
Control of Fuyang city. The serum samples from the
patients whose ages ranged from 1-3 years old were ana-
lyzed in this study.
Neutralization assay
The methods for measuring EV71 neutralizing antibo-
dies on microtiter plates have been described previously
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Page 2 of 6[20-22]. Briefly, heat-inactivated (56°C for 30 min) sera
were serially diluted in two-fold steps in Eagle’s minimal
essential medium containing 2% fetal bovine serum
(MEM-2), with an initial serum dilution of 1:8. The tis-
sue culture infectious dose (TCID50)o ft h ev i r a ls t o c k s
was determined and then diluted 10-fold, 10
2-fold and
10
3-fold with MEM-2. Diluted sera and 100 TCID50 of
viral samples were combined (50 μl of each) and the
mixture was incubated at 37°C for 1 hour. The virus-
serum mixtures (total 200 μl) were then inoculated on
70%-confluent rhabdomyosarcoma cells in a 96-well
plate and monitored for the development of characteris-
tic cytopathic effects for 4 days. The neutralizing titer of
a particular serum and virus was defined as the recipro-
cal of 100% of the highest dilution that resulted in no
observable cytopathic effect.
A.
B.
Figure 1 Reverse cumulative distribution curves of neutralizing antibody titers in HFMD patients, healthy children and adults subjects
by microneutralization assay against EV71. A. HFMD patients were analyzed as one group. B. HFMD patients were further categorized into
mild group, severe group without pulmonary edema and severe group with pulmonary edema in accordance with their disease severity.
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accession number: HM064456.1) used in this study was
isolated from a patient with HFMD from Fuyang city of
Anhui province in 2008.
Statistics
GraphPad Prism 5 was used in statistic analysis and
graph preparations. P-values were calculated by student
T-test.
Discussion
Studies of animal models revealed that antibody
response plays a critical role in protection from EV71
infection [12-16]. Several seroepidemiological studies in
humans have revealed that seroprevalence of EV71 anti-
bodies increase with age [10,23,24], which supports the
idea that increased humoral immunity may prevent
adults from EV71 infection. Thus, it is of importance to
know how humans respond to EV71 infection and to
A.
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Figure 2 Neutralizing antibody titers in HFMD patients by microneutralization assay against EV71. A. HFMD patients were classified by
dates of onset of illness. B. Serum samples of HFMD patients taken one day after symptoms of illness appeared had significantly higher
antibody titers than control subjects (p < 0.05).
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Page 4 of 6what degree humoral immune responses play a role in
EV71 infection. We found that 23.7% of HFMD patients
had ≥ 1:128 antibody titers, but none of the healthy chil-
dren did. In addition, we found that 80% (4/5) of
patients had neutralizing antibody titers against EV71
above 1:16 one day after the onset of illness. Two days
after symptoms appeared, patients already had a level of
neutralizing antibodies (GMT = 79.5) comparable to
that of adults. In other words, humoral immune
response was already elicited when clinical symptoms
appeared. Interestingly, our data is in accordance with a
previous report showing that neutralizing antibody levels
are not correlated with HFMD severity [25]. However,
this current study was a retrospective investigation and
we only had a very small number of cases at early stages
of infection. Whether the neutralizing antibody
responses in patients to EV71 at early stages of infection
correlate to the clinical severity of the disease remains
to be determined by future investigations.
Previously Gomes et al. showed that only 40.8% of
HFMD patients less than 3 years old had levels of neu-
tralizing antibody ≥ 1:8 [26]. Their results are not con-
sistent with the results in this study or with the results
reported by Chang et al [25]. This discrepancy may
result from technical problems by using different EV71
isolates. They used classic EV71 strains (BrCr) but not a
contemporary circulating EV71 isolate. In addition, the
pathogens causing HFMD in the Brazilian study may
not be only EV71 since they did not specify in the study.
Recently, a clinical trial for an EV71 vaccine has been
officially approved in China (http://clinicaltrials.gov/ct2/
show/NCT01267903). While there has been no clinical
trial thus far for the EV71 vaccine, it is imperative to
know what level of neutralizing antibody should be
achieved in children after EV71 vaccination and the
importance of cellular immunity in protection from
EV71 infection. Adults are rarely infected with EV71
[27], thus they appear to have immunity against EV71
infection. Only 83.3% of healthy adults in this study
were antibody-positive to EV71 (≥ 1:8 antibody titer).
Even HFMD patients were not all positive (93.2%). In
addition, 18.7% of HFMD patients did not have antibody
titers ≥ 1:16. Furthermore, similar to a previous study by
Chang et al., we found that there was no correlation
between the severity of the disease and neutralizing anti-
body levels. Thus, one may wonder, other than neutra-
lizing antibodies, additional immune mechanisms may
also contribute to the immunity against EV71 infection
in humans.
Interestingly, both human leukocyte antigen serotypes,
HLA-A33 (class I) and HLA-DR17 (class II), are signifi-
cantly associated with EV71 infection, suggesting cellular
immune responses may play an important role in
human immunity against EV71 infection [28]. In
addition, a previous study found that the most severe
EV71 cases, characterized by with pulmonary edema,
had lower cellular antigen-specific Th1 cytokines
coupled with a lower lymphocyte proliferation response
to EV71 antigen in comparison to milder cases, which
suggests that cellular immune responses are correlated
to the clinical severity of HFMD [25]. Thus, induction
of both humoral and cellular immunity should be con-
sidered in vaccine development and further analyzed by
clinical trials.
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EV71: Enterovirus 71; HFMD: Hand, foot and mouth disease; GMT: geometric
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